The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1273
Fluticasone Furoate (Veramyst) for Allergic Rhinitis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

Fluticasone furoate nasal spray (Veramyst – GSK) is now available for once-daily treatment of seasonal and perennial allergic rhinitis in adults and children ≥2 years old. It is similar to fluticasone propionate nasal spray (Flonase, and others), which is now available generically.

PHARMACOLOGY — In vitro, the binding affinity of fluticasone furoate for the glucocorticoid receptor is 1.7 times that of fluticasone propionate, and it is a more potent inhibitor of inflammatory mediators.1

CLINICAL STUDIES — Fluticasone furoate 110 mcg (2 sprays in each nostril) once daily was evaluated in 3 randomized, double-blind 2-week trials in a total of 886 patients ≥12 years old with seasonal allergic rhinitis (SAR).2-4 In all 3 trials, the active drug was significantly more effective than the nasal spray vehicle in improving ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Fluticasone Furoate (Veramyst) for Allergic Rhinitis
Article code: 1273b
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian